GlassScriptPhysician profile
Matthew W Miller
NPI 1225032964
$1,335.61
in general payments reported to CMS, 2019-2025
19 companies · $77.26 in 2025
The $77.26 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $160 · 2021: $128 · 2022: $104 · 2023: $333 · 2024: $335 · 2025: $77.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $746.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $745.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $402.53 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $190.35 | 2019-2024 | Jardiance, Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals LP | $155.58 | 2019-2024 | Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.94 | 2019-2024 | Jardiance, Tradjenta |
| Stryker Corporation | $77.26 | 2025 | Artix Mt, Flowtriever |
| Glaxosmithkline, LLC. | $60.04 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Merck Sharp & Dohme LLC | $52.09 | 2023-2024 | Gardasil 9, Vaxelis, Vaxneuvance |
| Pfizer INC. | $40.49 | 2020-2024 | |
| Astellas Pharma US INC | $38.12 | 2023-2024 | Veozah |
| Novartis Pharmaceuticals Corporation | $30.62 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $30.57 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $26.86 | 2019 | |
| Abbvie INC. | $26.75 | 2023 | |
| Abbott Laboratories | $23.48 | 2024 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $21.21 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $15.27 | 2024 | Voquezna |
| Alkermes, INC. | $13.47 | 2021 | |
| Dynavax Technologies Corporation | $12.18 | 2020 | |
| Amgen INC. | $11.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.